Orbsen Therapeutics introduces REDDSTAR FP7 at the Irish Cytometry Society 2014 Annual Meeting

Post 31 of 40

Orbsen Scientist, Dr. Lisa O’ Flynn delivered a presentation entitled ‘CD362: a functional marker for MSC isolation & therapeutic differentiation’ as part of the Irish Cytometry Society’s annual meeting in Astra Hall, University College Dublin on 26 February  2014.

Lisa O'Flynn

Dr. O’ Flynn’s talk provided a succinct background of CD362 and highlighted the importance of CD362 in developing Orbsen Therapeutics’ mesenchymal stromal cell (MSC) isolation and sorting strategies from multiple species and tissues. This work also highlights CD362 as a potentially useful marker to enable MSC donor selection.

Lisa concluded that CD362 is a functional MSC marker enabling the prospective isolation of a defined MSC population form multiple species and tissues. CD362 has the potential as a molecular target to enhance MSC efficacy and monitor MSC therapeutic potency.  Dr O’Flynn also highlighted the collaboration between Orbsen and Miltenyi Biotec to develop MACSQuant Tyto Cell Sorter for therapeutic applications within the EU FP7 REDDSTAR Consortium. Currently, the therapeutic application of CD362+MSC are being investigated in 3 EU FP7-funded projects REDDSTAR (Diabetes), MERLIN (Liver disease), and DeCIDE (Haematopoietic Stem Cell Transplantation).